HNF4a controls growth, identity and response to KRAS inhibition in IMA [ChIP- seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 38 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 38 samples: 38 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE294572_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1250515 and SRA study SRP578440. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 38 sample titles: 38 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8911548 20899X1_1311G#5_KN_input_rep1
- GSM8911549 20899X2_1311G#5_KNH_input_rep1
- GSM8911550 20899X3_1311G#5_KN_FOXA1_rep1
- GSM8911551 20899X4_1311G#5_KNH_FOXA1_rep1
- GSM8911552 21021X1_1311G#5_KN_FOXA1_rep2
- GSM8911553 21021X2_1311G#5_KNH_FOXA1_rep2
- GSM8911554 21021X3_1311g#5_KN_input_rep2
- GSM8911555 21021X4_1311G#5_KNH_input_rep2
- GSM8911556 23754X1_1311g#5_KN Hnf4a_rep1
- GSM8911557 23754X2_1311g#5_KN_Input_rep1
- GSM8911558 23754X3_1311g#5_KN_Hnf4a_rep2
- GSM8911559 23754X4_1311g#5_KN_input_rep2
- GSM8911560 24131X1_429A_KN_input_rep1
- GSM8911561 24131X2_429A_KN_Hnf4a_rep1
- GSM8911562 24131X3_429A_KN_input_rep2
- GSM8911563 24131X4_429A_KN_Hnf4a_rep2
- GSM8911564 24137X1_GEMM_KN_HED798_FOXA1_rep1
- GSM8911565 24137X2_GEMM_KN_HED798_Hnf4a_rep1
- GSM8911566 24137X3_GEMM_KN_HED798_input_rep1
- GSM8911567 24515X1_GEMM_KN_HED934_input
- GSM8911568 24515X2_GEMM_KN_HED934_FOXA1_rep2
- GSM8911569 24515X3_GEMM_KN_HED934_FOXA2_rep1
- GSM8911570 24515X4_GEMM_KN_HED934_Hnf4a_rep2
- GSM8911571 24515X5_GEMM_KNH_HED968_input
- GSM8911572 24515X6_GEMM_KNH_HED968_FOXA1_rep2
- GSM8911573 24515X7_GEMM_KN_HED814_input
- GSM8911574 24515X8_GEMM_KN_HED814_FOXA2_rep2
- GSM8911575 24289X1_GEMM_KNH_HED931_FOXA1_rep1
- GSM8911576 24289X2_GEMM_KNH_HED931_FOXA2_rep1
- GSM8911577 24289X3_GEMM_KNH_HED931_input
- GSM8911578 24289X4_GEMM_KNH_HED897_input
- GSM8911579 24289X6_GEMM_KNH_HED897_FOXA2_rep2
- GSM9689277 25736X1_HCI_IMA03_KN_input_rep1
- GSM9689278 25736X2_HCI_IMA03_KN_Hnf4a_rep1
- GSM9689279 25736X3_HCI_IMA03_KN_FOXA1_rep2
- GSM9689280 25736X4_HCI_IMA03_KN_Hnf4a_rep2
- GSM9689281 25798X1_HCI_IMA03_KN_input_rep2
- GSM9689282 25798X2_HCI_IMA03_KN_FOXA1_rep1
- GSE287736 Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprograming of hepatocytes 138 samples shares hnf4a, controls
- GSE294827 A plastic EMP1⁺ to LGR5⁺ cell state conversion as a therapeutic bypass to KRAS-G12D inhibition in metastatic colorectal cancer 81 samples shares kras, inhibition
- GSE287688 Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprograming of hepatocytes [RNA-seq] 68 samples shares hnf4a, controls
- GSE294216 Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Aberrant Histone Acetylation and Increased Sensitivity to BET Inhibition 36 samples shares kras, inhibition
- GSE336609 KRAS inhibition is an effective therapy for appendiceal adenocarcinoma 22 samples shares kras, inhibition
- GSE71225 EZH2 inhibition as a targeted therapy for H3K27M mutant pediatric gliomas [ChIP-seq] 13 samples shares inhibition, chip
- GSE218716 EZH2 gain-of-function mutations distort H3K27me3 landscapes and transform transcriptional responses to PRC2 inhibition [ChIP-Seq/Cut&Run-Seq] 156 samples shares inhibition, chip
- GSE248942 Spatiotemporal control of SMARCA5 by a MAPK-RUNX1 axis distinguishes mutant KRAS-driven pancreatic malignancy from tissue regeneration (ATAC-Seq) 123 samples shares kras
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.